{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-101093","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2021-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.669262+00:00","generated_at":"2026-06-29T20:27:57.054406+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Twist Bioscience Q3 revenue $35M (+65% YoY); raises FY2021 guidance","bullets":["Revenue $35.0M vs $21.2M YoY; orders $39.1M (+58% YoY).","Net loss $40.0M ($0.82/share) vs $28.2M ($0.67) YoY.","Gross margin 40%; cash $519.4M; raising FY2021 revenue guidance.","Shipped 107,000 genes (vs 83,000 YoY); acquired iGenomX for NGS tools.","Began shipping synthetic SARS-CoV-2 Delta RNA controls; appointed Dr. Melissa Starovasnik to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-101093","json":"https://secwatch.observer/filing/0001104659-21-101093.json","markdown":"https://secwatch.observer/filing/0001104659-21-101093.md","text":"https://secwatch.observer/filing/0001104659-21-101093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921101093/0001104659-21-101093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921101093/tm2123937d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T20:27:57.054406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}